- Depomed Plunges After Serada Results: Still An Attractive Buying Opportunity
- Platform and Specialty Pharmaceutical Companies Could Strengthen in Face of Big Pharma's Patent Cliff
- Strategies and Outlook for Xenoport's Upcoming FDA PDUFA Date
- Despite Abbott Parting With Gralise, Depomed's Future Looks Bright
- Pharmaceutical Companies Reformulate Pain Products: How Investors Can Benefit
Tro Kalayjian
Tro Kalayjian
Stop FollowingTro Kalayjian
ABOUT
Dr. Tro Kalayjian is currently the incoming Chief Resident at Greenwich Hospital, in an Internal Medicine Residency Program. He has worked on several clinical research projects, including; a systemic review comparing treatment options for neuropathic pain, and a clinical trial that sought to establish a relationship between post-exercise ABI and a positive nuclear stress test. He has added interest in Sports Medicine. He has volunteered in the elite-athlete medical tent for the NYC marathon. He also founded a 3000 square foot wellness facility for TouroCOM in NYC. He has worked with various fitness centers to promote health and wellness plans including New York Sports Club and Dolce International, among others.
...More
Tro is also a founding member of Chimera Research Group, an independent research firm focusing on catalysts in biotechnology and pharmaceuticals, primarily on special situations. He was a contributing writer for Seeking Alpha from 2008 to 2011, and has been recognized as an Opinion Leader in the Healthcare Sector. In 2012, he was named one of the Top 50 voices in biotech by Fierce Markets. His past work experience also includes research services management for the Smilow Research Center at New York University Medical Center and for the Departments of Biology and Chemistry at New York University.
In 2001, Tro received a Certification of Merit from the New York State Assembly. In 2009, he received a Honorable Citation from the New York City - City Council.
Tro has added interests in Karate, Ju-Jitsu and participated in cross-country running through high-school and college.
Follow Me On:
LinkedIn - http://www.linkedin.com/in/trokalayjian
Chimera Research Group - https://www.ChimeraResearchGroup.com
Twitter - http://www.twitter.com/trokalayjianCRG
**Opinions and Statements made here are personal and not professional, they do not represent the opinions of Tro Kalayjian's employers**
...More
Tro is also a founding member of Chimera Research Group, an independent research firm focusing on catalysts in biotechnology and pharmaceuticals, primarily on special situations. He was a contributing writer for Seeking Alpha from 2008 to 2011, and has been recognized as an Opinion Leader in the Healthcare Sector. In 2012, he was named one of the Top 50 voices in biotech by Fierce Markets. His past work experience also includes research services management for the Smilow Research Center at New York University Medical Center and for the Departments of Biology and Chemistry at New York University.
In 2001, Tro received a Certification of Merit from the New York State Assembly. In 2009, he received a Honorable Citation from the New York City - City Council.
Tro has added interests in Karate, Ju-Jitsu and participated in cross-country running through high-school and college.
Follow Me On:
LinkedIn - http://www.linkedin.com/in/trokalayjian
Chimera Research Group - https://www.ChimeraResearchGroup.com
Twitter - http://www.twitter.com/trokalayjianCRG
**Opinions and Statements made here are personal and not professional, they do not represent the opinions of Tro Kalayjian's employers**
SNAPSHOT
- Description: Independent / boutique research firm analyst. Trading frequency: Daily
- Interests: Stocks - long, Stocks - short
COMPANY
Chimera Research Group, Inc. Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early ...More
stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.
BLOG
Currently, there are no blog details for Tro Kalayjian.
Book
Currently, there are no book details for Tro Kalayjian.
Latest Comments
more »
- I think you raise several i... on Depomed Plunges After Serada Results: Still An ...
- Internal Medicine is my spe... on Depomed Plunges After Serada Results: Still An ...
- I am currently enrolled in ... on Depomed Plunges After Serada Results: Still An ...
- For DNDN, it ended up in a ... on Depomed Plunges After Serada Results: Still An ...
- I believe that Dr. Sweeny m... on Depomed Plunges After Serada Results: Still An ...
Latest comments on Tro's Articles
- highwave on Depomed's Stock Price Is a Gift Following FDA A...
- McBride on Bionovo Completes Financing, Announces Plan of ...
- Couch on Pharmaceutical Companies Reformulate Pain Produ...
- McBride on Bionovo Completes Financing, Announces Plan of ...
- McBride on Bionovo Completes Financing, Announces Plan of ...
LATEST ARTICLES & INSTAPOSTS
more »

